Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.03) by 1533.33 percent. This is a 131.16 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $108.019 million which missed the analyst consensus estimate of $117.127 million by 7.78 percent. This is a 405.73 percent increase over sales of $21.359 million the same period last year.